News
(RTTNews) - Applied Molecular Transport Inc. (AMTI) reported top-line phase 2 results from the MARKET combination trial for AMT-101 in biologic-naïve patients with moderate-to-severe ulcerative ...
--Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, today announced additional Phase 1 b data for oral AMT-101 in ulcerative colitis patients. AMT presented the data in ...
The Phase 2a study will include approximately 100 adult patients with moderate to severely active UC who will be randomized 2:1 to either receive oral AMT-101 or placebo for 12 weeks of treatment ...
(RTTNews) - Applied Molecular Transport Inc. (AMTI) reported top-line phase 2 results from the MARKET combination trial for AMT-101 in biologic-naïve patients with moderate-to-severe ulcerative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results